{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T01:10:21Z","timestamp":1754183421620,"version":"3.41.2"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis preceded by bronchial asthma or allergic sinusitis and accompanied by peripheral blood eosinophilia. Immunosuppressive drugs, such as cyclophosphamide in addition to high-dose glucocorticoids (GCs), are recommended for induction of remission in patients with severe EGPA. Although mepolizumab is widely recognised as remission induction therapy in nonfatal\/nonorgan disabling or relapsed\/refractory EGPA, its efficacy and safety in induction of remission for severe cases have been ambiguous. In this context, we report a case of myeloperoxidase antineutrophil cytoplasmic antibody-positive severe EGPA in which the patient had a favourable course using mepolizumab as an induction remission therapy. The patient, a 74-year-old man, had myeloperoxidase antineutrophil cytoplasmic antibody-positive severe EGPA with alveolar haemorrhage. High-dose GCs and intravenous cyclophosphamide were started as remission induction therapy. However, after the initiation of intravenous cyclophosphamide, alveolar haemorrhage worsened, and there was development of opportunistic infections, such as aspergillus and cytomegalovirus antigenaemia. Treatment with the antifungal drug voriconazole and the antiviral drug ganciclovir was started for opportunistic infection, and the treatment for EGPA was switched from intravenous cyclophosphamide to mepolizumab. As a result, alveolar haemorrhage improved, GCs were reduced, and the infection also improved. Mepolizumab as remission induction therapy for severe EGPA were thought to be appropriate and effective treatment in this case. However, the efficacy and safety of mepolizumab for this purpose require comprehensive evaluation.<\/jats:p>","DOI":"10.1093\/mrcr\/rxae088","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T07:32:32Z","timestamp":1734679952000},"source":"Crossref","is-referenced-by-count":0,"title":["MPO-ANCA-positive eosinophilic granulomatosis with polyangiitis complicated by alveolar haemorrhage treated with mepolizumab as an induction therapy: Case report"],"prefix":"10.1093","volume":"9","author":[{"given":"Mana","family":"Yoshida","sequence":"first","affiliation":[{"name":"Department of Neurology, Wakayama Medical University , Wakayama,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2076-1603","authenticated-orcid":false,"given":"Shigeru","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University , Wakayama,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayoko","family":"Tabata","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University , Wakayama,","place":["Japan"]},{"name":"Department of Dermatology, Wakayama Medical University , Wakayama,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wakayama Medical University , Wakayama,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Matsumiya","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University , Wakayama,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University , Wakayama,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuta","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Human Pathology, Wakayama Medical University , Wakayama,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Jinnin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wakayama Medical University , Wakayama,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University , Wakayama,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"key":"2025080201022990600_R1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025080201022990600_R2","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025080201022990600_R3","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-022-02845-3","article-title":"Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study","volume":"24","author":"Ueno","year":"2022","journal-title":"Arthritis Res Therapy"},{"key":"2025080201022990600_R4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","article-title":"Evidence-based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Emmi","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2025080201022990600_R5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1183\/09031936.00220413","article-title":"The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia","volume":"44","author":"Ortega","year":"2014","journal-title":"Eur Respir J"},{"key":"2025080201022990600_R6","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.alit.2019.06.004","article-title":"Update on eosinophilic granulomatosis with polyangiitis","volume":"68","author":"Furuta","year":"2019","journal-title":"Allergol Int"},{"key":"2025080201022990600_R7","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12515-9","article-title":"Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status","volume":"10","author":"Lyons","year":"2019","journal-title":"Nat Commun"},{"key":"2025080201022990600_R8","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3109\/14397595.2013.857582","article-title":"A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan","volume":"24","author":"Sada","year":"2014","journal-title":"Mod Rheumatol"},{"key":"2025080201022990600_R9","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/nri.2017.95","article-title":"Functions of tissue-resident eosinophils","volume":"17","author":"Weller","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"2025080201022990600_R10","doi-asserted-by":"crossref","first-page":"S806","DOI":"10.1097\/RHU.0000000000001453","article-title":"Reduction of myeloperoxidase-antineutrophil cytoplasmic antibody by mepolizumab in eosinophilic","volume":"27","author":"Komai","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"2025080201022990600_R11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1212\/WNL.0000000000011142","article-title":"Association between IL-5 levels and the clinicopathologic features of eosinophilic granulomatosis with Polyangiitis","volume":"96","author":"Nishi","year":"2021","journal-title":"Neurology"},{"key":"2025080201022990600_R12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/1346-8138.15709","article-title":"Early add-on administration of mepolizumab and intravenous immunoglobulin effective in treating eosinophilic granulomatosis with polyangiitis","volume":"48","author":"Ikeda","year":"2021","journal-title":"J Dermatol"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxae088\/61250595\/rxae088.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxae088\/61250595\/rxae088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxae088\/61250595\/rxae088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T05:02:39Z","timestamp":1754110959000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxae088\/7929973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxae088","relation":{},"ISSN":["2472-5625"],"issn-type":[{"type":"electronic","value":"2472-5625"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2024,12,21]]},"article-number":"rxae088"}}